Since 1999, Feb. 7 has marked National Black HIV/AIDS Awareness Day, drawing attention to the disproportionate impact of HIV ...

The long-running HIV market rivalry between Gilead Sciences and GSK is about to turn a new page this year as Gilead looks to ...

Last year marked the first time in Pfizer’s 175-year history that the drugmaker shelled out the requisite millions for ...

Following rumblings of a private equity bidding war late last year, Bain Capital has emer | Bain Capital is laying out 510 ...

Immunology superstar Dupixent, which first brought Regeneron and Sanofi together in 2007, has entered its megablockbuster era ...

If Fierce Pharma Marketing’s annual list of the top 10 biggest potential drug launches of the coming year is any indication, ...

Although Mounjaro and Zepbound have been headlining Lilly’s financial reports in recent years, the company’s roster of ...

Despite recent evidence of its financial turnaround, Thermo Fisher’s layoff spree will continue into 2025. | Despite recent ...

After recent launches of biosimilar versions of Eylea and Stelara, Amgen projects its biosimilar sales will reach $4 billion ...

Invivyd has teamed up with professional football coach Jim Harbaugh to tackle COVID-19 complacency. The biotech, which has ...

Just nine months after announcing a massive plan to cut costs, Bristol Myers Squibb has gone one better, revealing a new goal to save even more money.

Nephrologists jumped on the GLP-1 bandwagon well before Novo Nordisk won FDA approval for Ozempic in chronic kidney disease ...